Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

被引：118

作者：

Welsh, Paul ^{[2
]}

Grassia, Gianluca ^{[1
]}

Botha, Shani ^{[3
]}

Sattar, Naveed ^{[2
]}

Maffia, Pasquale ^{[1
,2
,4
]}

机构：

[1] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun &, Ctr Immunobiol, Glasgow, Lanark, Scotland

[2] Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland

[3] North West Univ, Potchefstroom Campus, Potchefstroom, South Africa

[4] Univ Naples Federico II, Dept Pharm, Naples, Italy

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2017年 / 174卷 / 22期

基金：

英国工程与自然科学研究理事会;

关键词：

C-REACTIVE PROTEIN; TUMOR-NECROSIS-FACTOR; CORONARY-HEART-DISEASE; SECRETORY PHOSPHOLIPASE A(2); INTERLEUKIN-1 RECEPTOR ANTAGONIST; APPARENTLY HEALTHY-MEN; SMOOTH-MUSCLE-CELLS; RHEUMATOID-ARTHRITIS; ASCORBIC-ACID; FACTOR-ALPHA;

D O I：

10.1111/bph.13818

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune-inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions.

引用

页码：3898 / 3913

页数：16

共 50 条

[1] Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, Oluremi N.
Everett, Brendan M.
CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (11)
[2] Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
Titanji, Boghuma
Gavegnano, Christina
Hsue, Priscilla
Schinazi, Raymond
Marconi, Vincent C.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (03):
[3] Inflammation, glucocorticoids and risk of cardiovascular disease
Buttgereit, Frank
Burmester, Gerd-Ruediger
Lipworth, Brian J.
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (01): : 18 - 19
[4] Inflammation modulation and cardiovascular disease prevention
Awan, Zuhier
Genest, Jacques
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (06) : 719 - 733
[5] Targeting Inflammation in Primary Cardiovascular Prevention
Carbone, Federico
Liberale, Luca
Bonaventura, Aldo
Cea, Michele
Montecucco, Fabrizio
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (37) : 5662 - 5675
[6] Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, Allison B.
Shoelson, Steven E.
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (01) : 83 - 93
[7] Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Zuzarte, Pedro
Duong, Angela
Figueira, Maria L.
Costa-Vitali, Atilio
Scola, Gustavo
CURRENT DRUG METABOLISM, 2018, 19 (08) : 674 - 687
[8] Statins and Inflammation in Cardiovascular Disease
Vogiatzi, Georgia
Oikonomou, Evangelos
Siasos, Gerasimos
Tsalamandris, Sotiris
Briasoulis, Alexandros
Androulakis, Emmanuel
Latsios, George
Papaioannou, Spyridon
Tsioufis, Konstantinos
Tousoulis, Dimitris
CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (46) : 7027 - 7039
[9] A Pilot Study To Examine the Effects of Smoking Cessation on Serum Markers of Inflammation in Women at Risk for Cardiovascular Disease
Reichert, Virginia
Xue, Xiangying
Bartscherer, Diane
Jacobsen, Daniel
Fardellone, Christine
Folan, Patricia
Kohn, Nina
Talwar, Arunabh
Metz, Christine N.
CHEST, 2009, 136 (01) : 212 - 219
[10] Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis
Liao, Katherine P.
Solomon, Daniel H.
RHEUMATOLOGY, 2013, 52 (01) : 45 - 52

← 1 2 3 4 5 →